利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

54 条记录 (耗时 0.035 秒)

    USE OF NATRIURETIC PEPTIDES FOR TREATING ANGIOEDEMA SYNDROMES
    34.
    发明申请
    USE OF NATRIURETIC PEPTIDES FOR TREATING ANGIOEDEMA SYNDROMES 有权
    用于治疗血管紧张素综合征的NATRIURETIC PEPTIDES的使用

    公开(公告)号：US20100204446A1

    公开(公告)日：2010-08-12

    申请号：US12733609

    申请日：2008-09-11

    申请人： Wolf-Georg Forssmann

    发明人： Wolf-Georg Forssmann

    IPC分类号： C07K14/58 ,  C07K14/575

    CPC分类号： A61K38/2242

    摘要： The present invention relates to the use of a natriuretic peptide, urodilatin, for treating patients suffering from acute drug induced angioedema, such as ACE inhibitor related adverse events. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously for 18 hours to 72 hours.

    摘要翻译： 本发明涉及利尿钠肽尿嘧啶苷用于治疗患有急性药物诱导的血管性水肿的患者，例如ACE抑制剂相关的不良事件。 优选地，将包含有效量的尿布菌素的组合物连续静脉内给药18小时至72小时。

    Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation
    35.
    发明申请
    Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation 审中-公开
    人趋化因子HCC-1多肽改善干细胞移植

    公开(公告)号：US20070244037A1

    公开(公告)日：2007-10-18

    申请号：US10577053

    申请日：2004-10-16

    申请人： Rudolf Richter ,  Reinhard Hen-Schler ,  Wolf-Georg Forssmann

    发明人： Rudolf Richter ,  Reinhard Hen-Schler ,  Wolf-Georg Forssmann

    IPC分类号： C07K14/52 ,  A61K38/19 ,  C07K16/00 ,  C12N1/00 ,  C12P21/00

    CPC分类号： A61K49/0008 ,  A61K38/00 ,  C07K14/523

    摘要： The invention discloses the human chemokine HCC-1, N-terminally truncated HCC-1 molecules and glycosylated HCC-1 which improve the homing of stem cells into the -bone marrow during stem cell transplantation. It is also provided a procedure for producing the polypeptides by recombinant techniques or chemical synthesis and for producing antibodies against such polypeptide. Furthermore, it is disclosed the modification of the polypeptide by coupling of amino acid residues and/or chemical groups or deleting amino-acids generating potent derivatives of the polypeptide. Another aspect of the invention provides a combination of the polypeptide of the present invention and a suitable pharmaceutical carrier for providing a therapeutically effective amount of the polypeptide for the treatment of various associated diseases. The invention concerns also the use of the HCC-1 molecules to increase engraftment of stem cells in the course of the stem cell transplantation performed in stem cell transplantation related diseases.

    摘要翻译： 本发明公开了人类趋化因子HCC-1，N-末端截短的HCC-1分子和糖基化的HCC-1，其在干细胞移植期间改善了干细胞归巢到骨髓中的归巢。 还提供了通过重组技术或化学合成生产多肽并产生针对这种多肽的抗体的方法。 此外，公开了通过偶联氨基酸残基和/或化学基团或删除产生多肽的有效衍生物的氨基酸来修饰多肽。 本发明的另一方面提供本发明的多肽和合适的药物载体的组合，用于提供治疗有效量的多肽用于治疗各种相关疾病。 本发明还涉及在干细胞移植相关疾病中进行的干细胞移植过程中使用HCC-1分子来增加干细胞的移植。

    Phosphorylated derivatives of cardiodilatin/ANF peptides
    39.
    发明授权
    Phosphorylated derivatives of cardiodilatin/ANF peptides 失效
    心脏抑素/ ANF肽的磷酸化衍生物

    公开(公告)号：US5461142A

    公开(公告)日：1995-10-24

    申请号：US95049

    申请日：1993-07-22

    申请人： Wolf-Georg Forssmann ,  Michael Gagelmann ,  Dieter Hock

    发明人： Wolf-Georg Forssmann ,  Michael Gagelmann ,  Dieter Hock

    IPC分类号： A61K38/00 ,  C07K14/58 ,  A61K38/22 ,  C07K1/04 ,  C07K1/113

    CPC分类号： C07K14/58 ,  A61K38/00

    摘要： Described are derivatives of the precursor peptide of the cardiodilatin/atrial sodiuretic factor (CDD-ANF) or fragments thereof which comprise at least the amino acid sequence of alpha-hANaP. The derivatives according to the present invention are compounds of the formula (I) ##STR1## X is a phosphate or thiophosphate group. R is NH.sub.2 or a peptide fragment from the amino acid sequence of gamma-hANaP. Radio-labelled derivatives are also possible. A method for the qualitative and/or quantitative determination of peptides containing the sequence of alpha-hANaP and a use of the compounds having the formula (I) as medicaments for various vaso- and renal related disorders are further described.

    摘要翻译： 描述了至少包含α-hANaP的氨基酸序列的心脏碘素/心房钠尿因子（CDD-ANF）或其片段的前体肽的衍生物。 根据本发明的衍生物是式（I）的化合物。X是磷酸酯或硫代磷酸酯基团。 R是NH2或来自γ-hANaP的氨基酸序列的肽片段。 放射标记的衍生物也是可能的。 进一步描述了定性和/或定量测定含有α-hANaP序列的肽的方法和使用具有式（I）的化合物作为各种血管和肾脏相关疾病的药物。

    Cardiodilatin fragment, process for preparing same and use thereof
    40.
    发明授权
    Cardiodilatin fragment, process for preparing same and use thereof 失效
    心钠素片段，其制备方法及其应用

    公开(公告)号：US5449751A

    公开(公告)日：1995-09-12

    申请号：US185240

    申请日：1994-01-24

    申请人： Wolf-Georg Forssmann ,  Jeanette M. Alt ,  Gerhard Becker ,  Franz Herbst

    发明人： Wolf-Georg Forssmann ,  Jeanette M. Alt ,  Gerhard Becker ,  Franz Herbst

    IPC分类号： A61K38/00 ,  C07K14/58 ,  C07K14/00 ,  A61K38/16

    CPC分类号： C07K14/58 ,  A61K38/00 ,  Y10S530/834

    摘要： Described is a peptide fragment which comprises the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP) and is formed in the kidney. The fragment urodilatin (ANF/CDD 95-126) has the following amino acid sequence: ##STR1## wherein R.sup.1 and R.sup.2 each represent further peptide fragments of ANF/CDD 1-126 (gamma-hANaP). In the amino acid sequence R.sup.1 is Thr-Alo-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser and R.sup.2 is Asn-Ser-Phe-Arg-Tyr. Further described are processes for the preparation and/or recovery of the new peptide fragment and a medicament containing urodilatin (ANF/CDD 95-126 ) as well as medical indications of the medicament.

    摘要翻译： 描述了包含ANF / CDD 1-126（γ-hANaP）的氨基酸序列95-126并形成于肾中的肽片段。 片段尿苷酶（ANF / CDD 95-126）具有以下氨基酸序列：其中R1和R2各自代表ANF / CDD 1-126（γ-hANaP）的另外的肽片段。 在氨基酸序列中，R1是Thr-Alo-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser，R2是Asn-Ser-Phe-Arg-Tyr。 还描述了用于制备和/或回收新肽片段的方法和含有尿布洛林（ANF / CDD 95-126）的药物以及药物的医学适应症。